- Human papillomavirus (HPV, a group of more than 40 virus types) is a sexually transmitted viral infection occurring worldwide.
- Risk exists for unvaccinated, sexually active travelers, regardless of age. Previous infection with one HPV type does not prevent subsequent infection with other types.
- Symptoms include lesions in or on the skin, genitals, or mucous membranes.
- Consequences of infection may include cancer of the cervix, vagina, penis, anus, or throat.
- Prevention includes sexual abstinence; condoms are not fully protective.
- HPV vaccine is routinely given to both females and males (whether or not they have been sexually active) aged 11-25 years as a 2- or 3-dose series over a period of 6 or 12 months, depending on age at series initiation. Persons aged 27-45 years may, under certain circumstances, want to consider vaccination.
- Vaccine side effects are mild and include injection-site reactions, fever, and headache.
- Vaccine protection is long lasting; no booster dose is recommended.
HPV infection is the most common sexually transmitted infection (STI) in the U.S. HPV infections can range from common benign genital warts to cancers of the genital area, anus, and back of the throat (oropharyngeal) in men and women. Cervical cancer is the fourth most common cancer in women worldwide. Although treatments are available for the health problems caused by HPV, no cure exists for HPV infection itself.
HPVs are common worldwide. In the U.S., approximately 79 million people are currently infected with HPV and another 14 million still become infected each year. At least 50% of sexually active men and women become infected at some point in their lives.
HPV is sexually transmitted from person to person through genital and skin-to-skin contact or oral sex. A pregnant woman with genital HPV infection can pass the infection to her newborn during delivery, although this is rare. More than 40 different types of HPV exist; persons who are sexually active and already infected with 1 or more HPV types are still susceptible to primary infection by new HPV types.
Risk is highest for unvaccinated, sexually active males and females (regardless of age). Risk has more to do with risk of exposure than age, regardless of being in a monogamous relationship or not. However, persons in long-term, mutually monogamous sexual relationships are not likely to acquire a new HPV infection. Older persons also have a decreased risk of new exposures to infection because they have a lower likelihood of having new sex partners compared to younger persons. Certain populations, such as men who have sex with men, persons with HIV, and immunocompromised persons, may be at higher risk for conditions associated with HPV or may have a lower immune response to the vaccine.
Most people infected with HPV do not develop symptoms because the body's immune system clears HPV naturally within 1 to 2 years in most cases. HPV infections that are not cleared may result in common benign genital warts or warts in the throat.
Consequences of Infection
HPV infection increases the risk for developing cancer of the cervix (most common), vagina, penis, anus, or throat; identifying which cases will progress to cancer is not possible.
Need for Medical Assistance
Persons who develop symptoms of HPV infection should seek medical attention. No treatment exists for the virus itself, but treatments are available for diseases caused by HPV.
HPV vaccines are not intended to be used for treatment, and they only protect against the HPV types contained in the vaccines.
The most effective way to avoid HPV infection, in addition to vaccination, is avoidance of sexual contact. Condoms are not fully protective.
HPV vaccine (Gardasil 9; protective against 9 different HPV types) is routinely recommended for persons aged 11-12 years (with catch-up vaccination through age 26 years for those inadequately vaccinated) and for children 9 years and older who have a history of sexual abuse or assault. Ideally, the vaccine should be administered before potential exposure to HPV through sexual activity; however, persons who are sexually active should still be vaccinated. Although not routinely recommended for unvaccinated or inadequately vaccinated healthy adults aged 27-45 years, vaccination may be considered in this age group following shared clinical decision making between the patient and their health care provider.
In persons already infected with HPV, subsequent vaccination does not prevent progression to cancer, decrease the time to clearance of HPV infection, or treat HPV-related diseases.
Vaccination is not a substitute for regular cervical cancer screening in women. Duration of protection from HPV vaccination is long lasting; booster doses are not recommended.
The most common vaccine side effects are mild and include injection-site reactions (pain, redness, warmth, and swelling), fever, and headache. More significant side effects are rare.
Persons with underlying medical conditions or who have concerns about the vaccine should speak to their health care provider before vaccine administration.
The primary series consists of 2- or 3-doses given over a period of 6 to 12 months, depending on age at series initiation.
If earlier protection is needed, a 2- or 3-dose series over a period of 5 months (depending on age at series initiation) will provide protection for healthy persons.